Cargando…
Acute retinal necrosis following dexamethasone intravitreal implant (Ozurdex®) administration in an immunocompetent adult with a history of HSV encephalitis: a case report
BACKGROUND: Dexamethasone intravitreal implants (0.7 mg) (Ozurdex®, Allergan Inc., Madison, NJ) are FDA approved for managing macular oedema (ME) of retinal vein occlusion (RVO). The major complications associated with intravitreal Ozurdex® implant include increased intraocular pressure and cataract...
Autores principales: | Zhang, Zhi-Yong, Liu, Xiu-Yun, Jiang, Tao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310153/ https://www.ncbi.nlm.nih.gov/pubmed/32571253 http://dx.doi.org/10.1186/s12886-020-01514-w |
Ejemplares similares
-
Intravitreal Dexamethasone Implant (Ozurdex) in Coats’ Disease
por: Saatci, Ali Osman, et al.
Publicado: (2013) -
Intravitreal Dexamethasone Implant (Ozurdex) for Refractory Macular Edema Secondary to Retinitis Pigmentosa
por: Örnek, Nurgül, et al.
Publicado: (2016) -
Fractured dexamethasone implant (OZURDEX®) following intravitreal injection
por: Aljohani, Saud M., et al.
Publicado: (2021) -
Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment
por: Garweg, Justus G., et al.
Publicado: (2016) -
A New Side Effect of Intravitreal Dexamethasone Implant (Ozurdex®)
por: Eris, Erdem, et al.
Publicado: (2017)